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Simvastatin is a lipid-lowering agent used to treat hypercholesterolemia and to reduce the risk of heart disease. This study
scrutinized the beneﬁcial eﬀects of simvastatin on experimental diabetic cardiomyopathy (DCM), pointing to the role of
hyperglycemia-induced oxidative stress and inﬂammation. Diabetes was induced by intraperitoneal injection of streptozotocin
and both control and diabetic rats received simvastatin for 90 days. Diabetic rats showed signiﬁcant cardiac hypertrophy, body
weight loss, hyperglycemia, and hyperlipidemia. Serum creatine kinase MB (CK-MB) and troponin I showed a signiﬁcant
increase in diabetic rats. Simvastatin signiﬁcantly improved body weight, attenuated hyperglycemia and hyperlipidemia, and
ameliorated CK-MB and troponin I. Simvastatin prevented histological alterations and deposition of collagen in the heart of
diabetic animals. Lipid peroxidation and nitric oxide were increased in the heart of diabetic rats whereas antioxidant defenses
were decreased. These alterations were signiﬁcantly reversed by simvastatin. In addition, simvastatin decreased serum
inﬂammatory mediators and expression of NF-κB in the diabetic heart. Cardiac caspase-3 was increased in the diabetic heart
and decreased following treatment with simvastatin. In conclusion, our results suggest that simvastatin alleviates DCM by
attenuating hyperglycemia/hyperlipidemia-induced oxidative stress, inﬂammation, and apoptosis.
1. Introduction
Cardiovascular disease (CVD) is the leading cause of
morbidity and mortality in the world. Diabetes mellitus
(DM) is a major contributing factor to CVD and heart failure
[1]. A causative relationship between myocardial abnormali-
ties and diabetes has been well demonstrated [2]. Diabetic
cardiomyopathy (DCM) is the clinical condition associated
with cardiac abnormalities provoked by diabetes [2]. It has
been estimated that DCM aﬀects approximately 12% of the
diabetic patients and may lead to heart failure and death
[3]. Cardiac hypertrophy, oxidative stress, inﬂammation,
apoptosis, and myocardial interstitial ﬁbrosis are the major
features of DCM [4].
Persistent hyperglycemia in diabetes provokes excessive
production of reactive oxygen species (ROS) and inﬂamma-
tion which play a key role in DCM [5, 6]. Hyperglycemia
induces glucose auto-oxidation and surplus generation of
ROS. Hyperlipidemia can also increase ROS production
through stimulating nicotinamide adenine dinucleotide
phosphate (NADPH) oxidases and inducing leakage of the
mitochondrial electron transport chain [7]. Excess ROS
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activates protein kinase C and subsequently nuclear factor-
κB (NF-κB), leading to myocardial injury [5, 6]. NF-κB is
a redox-sensitive protein complexes with a central role in
inﬂammation [8]. Activated NF-κB promotes the tran-
scription and release of inﬂammatory mediators such as
tumor necrosis factor-α (TNF-α) and thereby provokes
myocardial inﬂammation [8].
Statins are hydroxymethylglutaryl coenzyme A (HMG-
CoA) reductase inhibitors with lipid-lowering eﬀect. Statins
are the ﬁrst-line treatment for coronary artery disease and
are widely prescribed to prevent hypercholesterolemia [9].
Studies have shown the beneﬁcial outcomes of statins on
the cardiovascular system. In this context, Liu et al. [10]
have recently reported that rosuvastatin postconditioning
can protect isolated hearts against ischemia-reperfusion
injury. Independently of their lipid-lowering eﬀects, chronic
pretreatment with statins preserved the integrity of micro-
vasculature after acute myocardial infarction [11]. Improved
myocardial perfusion and decreased infarction areas after
ischemic reperfusion have been associated with early and
chronic pretreatment with statins [11, 12]. The beneﬁcial
therapeutic outcomes of statins have been attributed to their
ability to activate protein kinase B and endothelial nitric
oxide synthase (eNOS) [13] and to attenuate oxidative stress
[14, 15]. Previous studies have shown that simvastatin
inhibits hypertrophy of cultured cardiomyocytes [16, 17]
and in isoproterenol-induced rats [15]. In addition, simva-
statin exerted protective eﬀect against cardiac hypertrophy
in a rat model of abdominal aortic constriction [18].
Recently, González-Herrera et al. [19] demonstrated that
simvastatin can improve the pathophysiological condition
in chronic Chagas cardiomyopathy experimental animal
model. However, the protective eﬀect of simvastatin against
DCM has not yet been reported. Therefore, this study scruti-
nized the possible cardioprotective eﬀect of simvastatin in a
rat model of DCM.
2. Materials and Methods
2.1. Chemicals and Reagents. Simvastatin, streptozotocin
(STZ), pyrogallol, reduced glutathione (GSH), malondialde-
hyde (MDA), thiobarbituric acid, and Griess reagent were
supplied by Sigma-Aldrich (USA). Cholesterol, high-density
lipoprotein (HDL) cholesterol, and triglyceride assay kits
were supplied by Accurex (Mumbai, India). Antibodies for
NF-κB p65 (Cat. number sc-372), caspase-3 (Cat. number
sc-7148), and β-actin (Cat. number sc-47778) were pur-
chased from Santa Cruz Biotechnology (USA). Other che-
micals and reagents were supplied by Sigma-Aldrich or
other standard suppliers.
2.2. Experimental Animals. Ten-week old male Wistar rats
weighing 160–180 g were included in this investigation.
The animals were supplied by the College of Pharmacy
at King Saud University (Riyadh, Saudi Arabia) and were
provided free access to standard laboratory diet of known
composition and water ad libitum. The rats were main-
tained at normal atmospheric temperature (23± 2°C) on
a 12h light/dark cycle. The experimental protocol and all
animal procedures were approved by the Institutional
Research Ethics Committee, College of Pharmacy at King
Saud University (Riyadh, Saudi Arabia).
2.3. Experimental Design and Treatments. Type 1 DM was
induced by a single intraperitoneal (i.p.) injection of
55mg/kg body weight STZ to overnight fasted rats. STZ solu-
tion was freshly prepared by dissolving in 0.1M cold citrate
buﬀer (pH 4.5). Diabetes was conﬁrmed through the
determination of blood glucose levels at 72 hr using MED-
ISAFE MINI blood glucose reader (TERUMO Corporation,
Tokyo, Japan). Rats with blood glucose levels higher than
200mg/dl were considered diabetic and selected for further
experiments. Diabetes was further veriﬁed by measuring
blood glucose levels 7 days after STZ injection. Normal con-
trol rats received a single i.p. dose of physiological saline.
Thirty-two rats (16 diabetic and 16 normal) were divided
into 4 groups (N = 8) as follows:
Group I (control): Nondiabetic rats received physiologi-
cal saline orally for 90 days.
Group II (SIM): Nondiabetic rats received simvastatin
(10mg/kg) [15] dissolved in saline by oral gavage for 90 days.
Group III (diabetic): Diabetic rats received physiological
saline by oral gavage for 90 days.
Group IV (diabetic + SIM): Diabetic rats received simva-
statin (10mg/kg) for 90 days.
2.4. Sample Collection and Preparation. Twenty-four hours
after the last treatment, overnight fasted rats were sacriﬁced
by cervical dislocation. Blood was collected and processed
to separate serum. Hearts were excised, washed, and weighed.
Samples from the heart were homogenized in cold
phosphate-buﬀered saline (10% w/v), and clear homogenate
was collected to assay MDA, nitric oxide (NO), GSH, and
superoxide dismutase (SOD). Other samples were collected
on neutral buﬀered formalin for histological and immuno-
histochemical processing while others were kept at −80°C
for Western blotting.
2.5. Biochemical Assays
2.5.1. Assay of Creatine Kinase MB (CK-MB) and Troponin I.
Serum CK-MB and troponin I were determined using spe-
ciﬁc ELISA kits supplied by EIAab (Wuhan, China).
2.5.2. Assay of Serum Lipids and Cardiovascular Risk Indices.
Total cholesterol [20], triglycerides [21], and HDL choles-
terol [22] were assayed in serum of normal and diabetic rats
using reagent kits purchased from Accurex (Mumbai, India).
Low-density lipoprotein (LDL) cholesterol level was deter-
mined using the formula
LDL cholesterol
= total cholesterol − triglycerides5 + HDL cholesterol
1
Very low-density lipoprotein (vLDL) cholesterol was
calculated using the formula
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vLDL cholesterol = triglycerides5 2
Cardiovascular risk indices [23] and atherogenic index of
plasma (AIP) were calculated as follows:
cardiovascular risk index 1 = total cholesterolHDL cholesterol ,





2.5.3. Assay of Tumor Necrosis Factor Alpha (TNF-α) and
C-Reactive Protein (CRP). Serum TNF-α and CRP were
determined using speciﬁc rat ELISA kits purchased from
Merck Millipore (USA) and Abcam (USA), respectively.
2.5.4. Assay of Lipid Peroxidation, NO, GSH, and SOD.
MDA, an index of lipid peroxidation, GSH, and SOD were
assayed in the heart homogenates according to the
methods described by Preuss et al. [24], Beutler et al. [25],
Marklund and Marklund [26], respectively. NO in the heart
homogenates was determined as nitrite content using Griess
reagent [27].
2.6. Histopathology and Immunohistochemistry. Immediately
after sacriﬁce, the hearts were excised, washed, and ﬁxed in
10% neutral buﬀered formalin for 24 hr. Five μm-thick paraf-
ﬁn sections were prepared, cut, and stained with hematoxylin
and eosin (H&E). Other sections were stained with Masson’s
trichrome. Stained heart sections were scanned and exam-
ined using light microscopy.
Other heart sections were blocked via incubation in 3%
hydrogen peroxide and washed in Tris-buﬀered saline
(TBS; pH 7.6). The slides were incubated with protein
block (Novocastra) to prevent nonspeciﬁc binding of anti-
bodies and probed with rabbit anti-caspase-3 (Santa Cruz
Biotechnology, USA). The sections were then probed with
anti-rabbit secondary antibody, washed, and counter-
stained with hematoxylin. Negative control sections were
similarly processed with omission of incubation with the
primary antibody.
2.7. Western Blot. To investigate the eﬀect of simvastatin on
NF-κB expression in the heart of normal and diabetic rats,
Western blotting was applied as we recently reported [28].
Brieﬂy, heart samples were homogenized in RIPA buﬀer con-
taining proteinase inhibitors. Total protein content was
assayed using Bradford reagent, and 40μg proteins were sep-
arated on SDS-PAGE, electrotransferred onto nitrocellulose
membranes and blocked in 5% skimmed milk in TBS Tween
20. The blocked membranes were probed with rabbit anti-
NF-κB p65 and mouse anti-β-actin primary antibodies
(Santa Cruz Biotechnology, USA). After washing, the mem-
branes were incubated with the secondary antibodies and
developed using enhanced chemiluminescence kit (Bio-Rad,
USA). The blots were scanned and intensity of the obtained
bands was quantiﬁed using ImageJ (NIH, USA). Results were
normalized to β-actin and presented as percent of control.
2.8. Statistical Analysis. Results were presented as mean
± standard error of the mean (SEM). All statistical compari-
sons were made by means of the one-way ANOVA test
followed by Tukey’s test post hoc analysis using GraphPad
Prism (GraphPad Software, CA, USA). A P value <0.05 was
considered signiﬁcant.
3. Results
3.1. Simvastatin Attenuates Body Weight Loss, Cardiac
Hypertrophy, and Hyperglycemia in Diabetic Rats. Diabetic
rats showed a signiﬁcant (P < 0 001) body weight loss when
compared with the control group (Figure 1(a)). Simvastatin
signiﬁcantly (P < 0 01) attenuated body weight loss in dia-
betic rats when supplemented for 90 days (Figure 1(a)). Nor-
mal rats that received simvastatin for 90 days showed
nonsigniﬁcant (P > 0 05) changes in body weight when com-
pared with the control group (Figure 1(a)).
Heart weight/body weight ratio (HW/BW) was signiﬁ-
cantly (P < 0 01) increased in diabetic rats when compared
with the control group; an eﬀect that was signiﬁcantly (P <
0 05) repressed by simvastatin (Figure 1(b)). Simvastatin
treatment for 90 days did not aﬀect the HW/BW of normal
rats as represented in Figure 1(b).
Blood glucose levels showed a signiﬁcant (P < 0 001)
increase when compared with the control rats (Figure 1(c)).
Ninety days after, diabetic rats exhibited a signiﬁcant (P <
0 001) increase in blood glucose when compared with the
control rats. Simvastatin-treated diabetic rats showed a sig-
niﬁcant (P < 0 001) improvement in blood glucose levels
when compared with the diabetic control rats (Figure 1(c)).
Supplementation of simvastatin to normal rats did not aﬀect
blood glucose levels.
3.2. Simvastatin Prevents Hyperglycemia-Induced Damage
and Collagen Deposition in the Diabetic Heart. To investi-
gate hyperglycemia-induced myocardial injury and the
possible protective role of simvastatin, we determined
circulating CK-MB and troponin I levels and performed
a histological study.
Diabetic rats showed signiﬁcantly (P < 0 001) increased
serum CK-MB. In contrast, diabetic rats treated with sim-
vastatin exhibited a marked (P < 0 001) improvement in
CK-MB (Figure 2(a)).
Similarly, diabetic rats showed a notable (P < 0 001)
elevation in circulating levels of troponin I as showed in
Figure 2(b). Treatment with simvastatin markedly (P <
0 001) improved serum troponin I levels in diabetic rats.
Treatment of normal rats with simvastatin did not induce
signiﬁcant changes in either CK-MB or troponin I.
Histopathological study of heart sections of normal
control rats revealed normal histological appearance of
both cardiomyocytes cytoplasm and nuclei (Figure 3(a)).
Normal rats treated with simvastatin exhibited normal heart
histology as showed in Figure 3(b). On the contrary, heart
sections of diabetic rats showed myocardial degeneration















































































Figure 1: Simvastatin attenuates body weight loss (a), cardiac hypertrophy (b), and hyperglycemia (c) in STZ-induced diabetic rats. Data are


















































Figure 2: Simvastatin decreases serum CK-MB (a) and troponin I (b) levels in STZ-induced diabetic rats. Data are M± SEM (N = 8).
∗∗∗P < 0 001. STZ: streptozotocin; SIM: simvastatin; CK-MB: creatine kinase MB; ns: nonsigniﬁcant.
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and pyknotic nuclei (Figure 3(c)). Simvastatin markedly
prevented diabetes-induced myocardial damage as depicted
in Figure 3(d).
The heart sections showing collagen deposition were rep-
resented in Figure 4. Control (Figure 4(a)) and simvastatin-
treated rats (Figure 4(b)) showed normal interstitial colla-
gen. Diabetic rats showed increased collagen deposition in
the endomysium, especially surrounding blood vessels
(Figure 4(c)). Diabetes-associated collagen deposition was
markedly prevented in the heart of diabetic rats treated
with simvastatin (Figure 4(d)).
3.3. Simvastatin Ameliorates Hyperlipidemia and Prevents
Atherogenesis in Diabetic Rats. The impact of simvastatin
on serum lipids and cardiovascular risk indices is depicted
in Figure 5.
Diabetic rats showed an atherogenic lipid proﬁle char-
acterized by signiﬁcant (P < 0 001) increase in serum tri-
glycerides (Figure 5(a)) and total (Figure 5(b)), LDL
(Figure 5(c)), and vLDL cholesterol (Figure 5(d)) when
compared with the normal control rats. HDL cholesterol
was signiﬁcantly (P < 0 001) declined in serum of STZ-
induced diabetic rats when compared with the control
group (Figure 5(e)). Treatment of the diabetic rats with
simvastatin signiﬁcantly (P < 0 001) reversed these lipid
proﬁle derangements.
To evaluate the impact of hyperlipidemia on the
heart and blood vessels and the protective eﬀect of sim-
vastatin, the cardiovascular risk indices and AIP were
determined. Cardiovascular risk indices showed a pro-
nounced (P < 0 001) increase in STZ-induced diabetic rats
(Figures 5(f) and 5(g)) and AIP (Figure 5(h)). Treatment
with simvastatin signiﬁcantly (P < 0 001) decreased cardio-
vascular risk indices and AIP of the diabetic rats.
Normal rats that received simvastatin for 90 days showed
nonsigniﬁcant (P > 0 05) changes in lipid proﬁle, cardiovas-
cular risk indices, and AIP.
3.4. Simvastatin Suppresses Diabetes-Induced Oxidative Stress
in the Diabetic Heart. The eﬀect of simvastatin on the myo-
cardial redox status of normal and diabetic rats was investi-
gated via assessment of MDA, NO, GSH, and SOD.
Diabetic animals exhibited a remarkable (P < 0 001)
increase in the myocardial MDA (Figure 6(a)) and NO
(Figure 6(b)). Treatment with simvastatin signiﬁcantly (P <
0 001) decreased cardiac levels of MDA and NO in diabetic
rats. In normal rats, simvastatin administration for 90 days









Figure 3: Heart of (a) normal control rats and (b) normal rats treated with simvastatin showing normal histological appearance of both
myocardial cell cytoplasm (arrow) and nuclei (arrow head), (c) STZ-induced diabetic rats showing many myocardial cells with
degenerated cytoplasm (arrow) and pyknotic nuclei (arrow head), and (d) diabetic rats treated with simvastatin showing decreased
degeneration of myocardial cell cytoplasm (arrows) and nuclei (arrow heads). (H&E).
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The antioxidant GSH was signiﬁcantly (P < 0 001)
declined in the heart of STZ-induced diabetic rats when com-
pared with the control group (Figure 6(c)). In addition, dia-
betic rats showed a signiﬁcant (P < 0 01) decrease in cardiac
SOD activity (Figure 6(d)). Simvastatin, supplemented for
90 days, signiﬁcantly ameliorated GSH content (P < 0 001)
and SOD (P < 0 05) activity in the heart of diabetic rats while
exerted nonsigniﬁcant (P > 0 05) eﬀect in normal rats.
3.5. Simvastatin Inhibits Inﬂammation and Myocardial
Apoptosis in Diabetic Rats. The ameliorative eﬀect of sim-
vastatin on diabetes-associated inﬂammation was explored
via determination of serum TNF-α and CRP levels and
cardiac NF-κB expression. TNF-α (Figure 7(a)) and CRP
(Figure 7(a)) were signiﬁcantly (P < 0 001) increased in
diabetic rats. Simvastatin signiﬁcantly decreased TNF-α
and CRP in serum of the STZ-induced diabetic rats. Oral
administration of simvastatin to control rats exerted non-
signiﬁcant (P > 0 05) eﬀects on serum TNF-α and CRP.
Protein expression of NF-κB was signiﬁcantly (P < 0 001)
upregulated in the heart of STZ-induced diabetic rats
(Figure 7(c)). Diabetic rats treated with simvastatin showed
a signiﬁcant (P < 0 001) downregulation of cardiac NF-κB
expression. Simvastatin did not aﬀect NF-κB expression
levels in the heart of control rats (Figure 7(c)).
To investigate the protective eﬀect of simvastatin on
myocardial apoptosis in diabetes, the expression of caspase-
3 was assessed by immunohistochemistry (Figure 7(d)).
Heart sections of normal (Figure 7(d)-A) and simvastatin
supplemented rats (Figure 7(d)-B) did not show caspase-3
immunopositive reaction of cardiomyocytes. STZ-induced
diabetic rats showed marked increase in caspase-3 immuno-
positive stained cardiomyocytes (Figure 7(d)-C), an eﬀect
that was prevented by simvastatin (Figure 7(d)-D).
4. Discussion
Cardiomyopathy is an independent complication of DM
which occurs in the absence of other heart diseases [29].
Hyperglycemia/hyperlipidemia-induced oxidative stress,
inﬂammation, and apoptosis are probably involved in the
pathogenesis of DCM [30, 31]. Here, we demonstrated the
ameliorative potential of simvastatin on DCM in a rat model
of STZ-induced diabetes. We provide the evidence that
simvastatin ameliorates DCM via its ability to mitigate
hyperglycemia, hyperlipidemia, oxidative stress, inﬂamma-
tion, and apoptosis.
The principal approach to control DM is lowering
blood glucose levels. Here, STZ-induced diabetic rats









Figure 4: Heart of (a) control rats, (b) simvastatin-supplemented rats revealing normal amount and distribution of interstitial collagen
(arrow), (c) STZ-induced diabetic rats with marked increase in the amount of collagen tissue in the endomysium especially surrounding
blood vessels (arrows), and (d) diabetic rats treated with simvastatin showing decreased collagen deposition (arrow). (Masson’s trichrome).































































































































































































































Figure 5: Simvastatin ameliorates hyperlipidemia and prevents atherogenesis in STZ-induced diabetic rats. Data are M± SEM (N = 8).
∗∗∗P < 0 001. STZ: streptozotocin; SIM: simvastatin; T cholesterol: total cholesterol; LDL: low-density lipoprotein; HDL: high-density
lipoprotein; vLDL: very low density lipoprotein; ns: nonsigniﬁcant.
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concomitantly declined body weight as we previously
reported [32]. Treatment with simvastatin signiﬁcantly
improved blood glucose levels in diabetic rats. Similar
ﬁndings have been described in type 1 [14] and type 2
diabetic rodent models [33]. The antihyperglycemic eﬀect
of statins may be attributed to their pleotropic eﬀects,
including increased insulin release and improved insulin
signaling and protection of pancreatic β-cells from ROS
[34, 35]. Additionally, statins have been proven to inhibit
the activity of dipeptidyl peptidase IV (DPP-IV) [36]. In
the same context, we have recently reported attenuated
hyperglycemia and DCM in diabetic rats treated with the
DPP-IV inhibitor sitagliptin [32]. The improved glycemic
status following simvastatin treatment may have contrib-
uted to the alleviated body weight.
Oxidative stress and inﬂammation are known to promote
cardiomyocyte hypertrophy in hyperglycemic conditions
[37]. Here, diabetic rats exhibited cardiac hypertrophy evi-
denced by the increased HW/BW ratio. Similar ﬁndings have
been reported in our recent study [32]. In our study, cardiac
hypertrophy was associated with increased TNF-α and car-
diac NF-κB expression. TNF-α has been reported to reduce
degradation and increase synthesis of proteins in feline
cardiomyocytes. These derangements occur through a mech-
anism involving preserved interaction between the extracel-
lular matrix and cell integrins [38] and activation of NF-κB
[39]. Increased rate of fatty acid (FA) oxidation in the
diabetic myocardium results in lipid accumulation and
subsequently cardiac hypertrophy [40]. Myocardial hyper-
trophy has also been reported to occur after 8 weeks of
diabetes [41]. Simvastatin treatment prevented cardiac
hypertrophy in the diabetic rats. This eﬀect might be attrib-
uted to the attenuated inﬂammation and oxidative stress. In
consistent with our ﬁndings, simvastatin has prevented
isoproterenol-induced cardiac hypertrophy in rats as we
previously reported [15]. In addition, Liu et al. [18] showed
the capacity of simvastatin to prevent in vitro and in vivo
myocardial hypertrophy.
Hyperglycemia provoked cardiomyocyte damage as
evidenced by the myocardium degeneration and pyknotic
nuclei and elevated serum CK-MB and troponin I. These
derangements are direct consequences of hyperglycemia-
induced oxidative stress, inﬂammation, and other alterations.
Elevated serum level of CK-MB is a powerful and sensitive
tool to predict the risk of cardiac complications [42]. The



























































































Figure 6: Simvastatin suppresses hyperglycemia-induced oxidative stress in the heart of STZ-induced diabetic rats. Data are M± SEM
(N = 8). ∗P < 0 05, ∗∗P < 0 01, and ∗∗∗P < 0 001. STZ: streptozotocin; SIM: simvastatin; MDA: malondialdehyde; NO: nitric oxide; GSH:
reduced glutathione; SOD: superoxide dismutase; ns: nonsigniﬁcant.


















































































Figure 7: Simvastatin inhibits inﬂammation and myocardial apoptosis in STZ-induced diabetic rats. Simvastatin decreased serum levels
of (a) TNF-α and (b) CRP and (c) NF-κB p65 expression in the heart of diabetic rats. Data are M± SEM (N = 8). ∗∗∗P < 0 001. STZ:
streptozotocin; SIM: simvastatin; TNF-α: tumor necrosis factor alpha; CRP: C-reactive protein; NF-κB: nuclear factor kappaB; ns:
nonsigniﬁcant. (d) Photomicrographs of caspase-3 immunostained sections in the heart of (A) control rats, (B) normal rats treated
with simvastatin showing immune-negative reaction (arrow), (C) STZ-induced diabetic rats showing strong immunopositive reaction in
many myocardial cells (arrows), and (D) diabetic rats treated with simvastatin showing marked decrease in caspase-3 immune-positivity
of the myocardial cells (arrow).
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induced increase in permeability are associated with elevated
circulating CK-MB and troponin I [43]. Previous research
from our lab showed increased CK-MB and troponin I
in serum of rat models of myocardial hypertrophy [15]
and DCM [32]. Hyperlipidemia is another factor that con-
tributes to cell death and cardiac dysfunctions in diabetes.
Hyperlipidemia promotes the deposition of triglycerides
and cholesterol in the myocardium and inﬂuences cardiac
toxicological consequences [44]. Simvastatin signiﬁcantly
ameliorated indices of myocardial damage in diabetic
animals. Therefore, reduced CK-MB and troponin I in
simvastatin-treated diabetic rats supports the role of lipid-
lowering agents in reducing hyperglycemia/hyperlipidemia-
induced myocardial damage.
Given its role in inducing the production of ROS [45] and
deposition of lipids in the myocardium [44], hyperlipidemia
exerts a direct impact on the myocardium and increases the
risk of coronary heart disease [46]. Here, STZ-induced
diabetic rats exhibited an atherogenic lipid proﬁle character-
ized by signiﬁcant increases in serum cholesterol, triglycer-
ides, LDL cholesterol, and vLDL cholesterol. In contrast,
the cardioprotective HDL cholesterol [47] was signiﬁcantly
declined in the diabetic rats. Moreover, diabetic rats
showed signiﬁcantly increased values of the cardiovascular
risk indices and AIP which is a frequently used predictor
of atherosclerosis [48]. Simvastatin signiﬁcantly reduced
hyperlipidemia, cardiovascular risk indices, and atherogenic
index in diabetic rats, indicating its potent lipid-lowering,
antiatherogenic, and cardioprotective eﬀects.
Counteracting oxidative stress is another mechanism we
assumed have mediated the protective eﬀect of simvastatin
on DCM. Hyperglycemia/hyperlipidemia-induced produc-
tion of ROS and reactive nitrogen species (RNS) constitutes
a major contributing factor in the development of DCM.
Hyperglycemia promotes generation of ROS and RNS in
the mitochondria [49], and increased cardiac FAs activate
NADPH oxidases and induce leakage of the mitochondrial
electron transport chain [7]. Excess ROS promote upsurges
in lipid peroxidation and consequently alter membrane
structure and enzyme activity [50]. In the present study,
diabetic rats exhibited signiﬁcantly elevated lipid peroxida-
tion and NO in the myocardium. NO and superoxide rad-
icals can react and produce peroxynitrite, leading to DNA
fragmentation and protein damage [51]. Diabetic rats
exhibited reduced cardiac GSH, indicating its overutiliza-
tion in the redox-challenged cellular microenvironment.
GSH depletion induces further oxidative damage and
necrotic cell death [52, 53]. SOD, an enzyme catalyzing
the dismutation of superoxide, showed declined activity in
the diabetic heart. Simvastatin reduced lipid peroxidation
and NO and alleviated antioxidants in the diabetic heart.
Accordingly, simvastatin decreased lipid peroxidation and
increased hepatic and renal GSH levels in diabetic rats
[14]. We have previously demonstrated the ability of simva-
statin to decrease ROS generation and enhance antioxidant
defenses in a rodent model of cardiac hypertrophy [15].
Therefore, the eﬃcacy of simvastatin to attenuate oxidative
stress may mediate, at least in part, its protective eﬀect
against DCM.
Cardiac inﬂammation, apoptosis, and ﬁbrosis have been
deﬁned in the diabetic heart [31]. Seddon et al. [54] reported
that cardiac inﬂammation occurs as a consequence of
hyperglycemia-induced excessive ROS generation in diabe-
tes. In our study, diabetic rats showed a signiﬁcant increase
in circulating TNF-α and CRP. Previous experimental stud-
ies demonstrated the contributing role of chronic inﬂamma-
tory status in DCM [55–57]. TNF-α has been reported to
exert a crucial role in the development of myocardial hyper-
trophy and dysfunction [55–57]. In the study of Bozkurt
et al. [58], exogenous administration of TNF-α induced
in vivo cardiac inﬂammation and dysfunction. The role of
TNF-α in DCM has been further supported through observ-
ing similar eﬀects in a mouse model with cardiomyocyte-
speciﬁc TNF-α overexpression [59]. Additionally, in a
murine model of pressure overload, genetic disruption of
TNF-α hampered cardiac hypertrophy, dysfunction, and
ﬁbrosis [60]. In STZ-induced DCM, TNF-α antagonism pro-
tected against myocardial inﬂammation, leukocyte inﬁltra-
tion, and ﬁbrosis [61].
Elevated CRP in STZ-induced diabetic rats in the pres-
ent investigation was in agreement with the ﬁndings of pre-
vious studies showing increased serum CRP levels in
diabetic patients [62] and STZ-induced type 1 diabetic ani-
mals [63]. Interestingly, diabetic rats treated with simva-
statin showed signiﬁcantly reduced serum TNF-α and
CRP levels. Therefore, the beneﬁcial eﬀect of simvastatin
is connected to its ability to reduce inﬂammation. In accor-
dance, we have previously reported attenuated inﬂammation
in a rat model of cardiac hypertrophy following simvastatin
administration [15].
Next, we demonstrated the eﬀect of simvastatin on NF-
κB expression in the diabetic heart. In consistent with the
increased serum levels of TNF-α and CRP, cardiac NF-κB
was upregulated in the diabetic rats. Diﬀerent mechanisms
implicated in the establishment of inﬂammation in the dia-
betic myocardium were reported to converge towards NF-
κB activation. Hyperglycemia promotes NF-κB transcription
through activation of NADPH oxidase and production of
ROS [64], degradation of IκB [8], and activation of Erk1/2
[65] and mitogen-activated protein kinase (MAPK) [66].
Activated NF-κB induces the upregulation of TNF-α and
other molecules contributing to cardiovascular damage [8].
Increased circulating lipids may also contribute to NF-κB
activation in diabetes [67]. Treatment of the diabetic rats
with simvastatin prevented NF-κB activation in the myocar-
dium, conﬁrming its anti-inﬂammatory eﬃcacy. In an exper-
imental model of cardiac hypertrophy, we have reported the
ability of simvastatin to reduce NF-κB expression in the
heart. This anti-inﬂammatory eﬀect could be directly con-
nected to its lipid-lowering mechanism.
Hyperglycemia-induced ROS generation can induce
myocardial apoptosis and ﬁbrosis [32, 54]. Myocardial
inﬂammation promotes cardiomyocyte death and therefore
contributes to cardiac remodeling [37]. Here, diabetic rats
showed increased expression of the apoptosis marker
caspase-3 in the myocardium. Apoptosis in the diabetic heart
occurs as a direct result of sustained ROS production and
inﬂammation. In this context, Haudek et al. [68] reported
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that sustained TNF-α signaling provokes both intrinsic and
extrinsic cell death pathways, increases caspase-3 activation,
and promotes cardiomyocyte apoptosis. The proapoptotic
eﬀects of TNF-α are likely mediated via NF-κB activation
[69]. Simvastatin markedly prevented hyperglycemia-
induced cardiomyocyte apoptosis in STZ-induced diabetic
rats via attenuating inﬂammation and ROS production.
Histological examination of the diabetic heart revealed
myocardium degeneration and increased collagen deposi-
tion as we recently reported [32]. Oxidative stress, inﬂamma-
tion and cell injury are well-known causes of the cardiac
ﬁbrosis [61]. Cytokines and proﬁbrotic factors released by
cardiomyocytes and inﬂammatory cells stimulate ﬁbrosis in
the diabetic heart. Through its ability to activate WNT1
inducible-signaling pathway protein 1 (WISP1), TNF-α
directly induces proliferation of cardiac ﬁbroblast and
production of collagen [70]. In addition, the proﬁbrotic
eﬀects of cytokines have been shown to be boosted by ROS
[55, 57]. Treatment with simvastatin markedly reduced colla-
gen production and ﬁbrosis, probably through its dual ability
to enhance the antioxidant defenses and to reduce chronic
inﬂammation in the heart of diabetic rats. Accordingly,
statins have reduced cardiovascular events and mortality
in diabetic patients [71]. Atorvastatin reduced myocardial
inﬂammation and ﬁbrosis in a diabetic rat model [72].
This eﬀect was believed to be independent of atorvastatin’s
LDL cholesterol-lowering capacity [72]. Fluvastatin has also
been reported to attenuate cardiac dysfunction and myocar-
dial interstitial ﬁbrosis in diabetes [73]. Therefore, lipid-
lowering treatments seem to be eﬀective in the attenuation
of diabetes-associated cardiac ﬁbrosis and cell injury together
with a role in the primary prevention of the disease.
In conclusion, simvastatin has a protective eﬀect on
DCM. Simvastatin attenuated hyperglycemia/hyperlipid-
emia-induced oxidative stress and enhanced antioxidant
defenses in the myocardium of diabetic rats. Simvastatin
showed a strong modulatory eﬀect against cardiac hypertro-
phy, inﬂammation, apoptosis, and ﬁbrosis. Therefore, simva-
statin and possibly other lipid-lowering agents can protect
against DCM.
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